Efficacy and safety of 3D-therapy at HCV-related subcompensated liver cirrhosis (genotype 1b)

Aim of the study. To estimate efficacy and safety of 3D mode of interferon­free therapy in patients with subcompensated liver cirrhosis (LC) of HCV etiology (genotype 1b). Material and methods. Original study included the data of 66 patients (26 men and 40 women) with subcompensated LC of HCV etiology (genotype 1b) who underwent interferon­free therapy by ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin for 12 weeks (the latter was cancelled at receiving the new data on treatment efficacy after 4 weeks of therapy) in September, 2015, before the drug instruction was updated. Mean age of patients was 56.4±10.0 years. At onset of etiological therapy 21 patients (31.8%) had Child­Pugh score of 9, eleven patients (16.7%) had Child­Pugh 8, 34 patients (51.5%) had Child­Pugh 7. The causes of inefficacy of previous modes of combined antiviral therapy (CAT) included absence of virologic response in 43.9% of the cases, recurrence of HCV replication - in 30.3%, virological breakthrough - in 16.7%, development of serious adverse effects - in 9.1%. Taking into account the change of the group quantity during the course of therapy because of treatment cancellation for safety reasons and the subsequent assessment of its efficacy in patients with early treatment cancellation, the modified «intent­to­treat» (ITT) analysis was the basic method of results evaluation. Along with that «per protocol» (PP) analysis was carried out as well. Results. During the treatment course aviremia in 14 days was achieved in 53.8% of patients (in 35 patients of 65), prompt virologic response - at 79.7% (in 51 of 64 patients). All patients underwent complete 12 week course of CAT (n=60) and those for whom treatment was canceled for safety reasons (n=3) - in terms from 14 to 30 days - sustained virologic response (SVR) in 12 weeks and SVR in 24 weeks was registered. The assessment of liver function compensation degree in 6 months after CAT termination demonstrated 3 to 4 points reduction of the Child-Pugh Score in 21 patients (33.9 %), 1 to 2 points in 35 patients (56.5 %). According to the MELD score the clinical improvement was achieved in 66.1% of patients. The early treatment termination was caused by progression of hepatic encephalopathy symptoms and/or jaundice development (4 cases). Most cases of the progression­related treatment termination due to liver failure were reversible after CAT interruption. Three lethal outcomes after the early treatment termination and 1 patients death in follow­up period were registered. Conclusion. Antiviral therapy in 3D mode for subcompensated LC is highly effective not only in those patients who received complete treatment course, but also in those with early treatment secession. Profiling of 3D therapy safety demonstrated that development of serious adverse effects during the treatment is comparable to outcomes at natural course of subcompensated LC in the absence of etiological therapy.

HCV-инфекция, цирроз печени, противовирусная терапия, 3D-терапия, эффективность, безопасность

1. Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W., and Christensen, E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002; 97:2886-95.

2. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio P. et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112: 463-72.

3. Singal A.G., Volk M.L., Jensen D., Di Bisceglie A.M., and Schoenfeld P.S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010; 8: 280-8.

4. Thein H.H., Yi Q., Dore G.J. and Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48: 418-31.

5. Butt A.A., Yan P., Lo Re V. 3rd, Rimland D., Goetz M.B., Leaf D. et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015; 175: 178-85.

6. Davis G.L., Alter M.J., El-Serag H., Poynard T., and Jennings L.W. Aging of hepatitis C virus (HCV)infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138: 513-21.

7. Waziry R., Grebely J., Amin J., Alavi M., Hajarizadeh B., George J., Matthews GV., Law M., Dore GJ. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (20002014). J Hepatol. 2016 Aug 26. pii: S0168-8278(16)304421. doi: 10.1016/j.jhep.2016.08.010.

8. Kanwal F., Hoang T., Kramer J.R., Asch S.M., Goetz M.B., Zeringue A. et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011; 140: 1182-8.

9. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M. et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003; 39: 389-96.

10. Iacobellis A., Siciliano M., Perri F., Annicchiarico B.E., Leandro G., Caruso N. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007; 46:206-12.

11. Hézode C., Fontaine H., Dorival C. et al. CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132-42.

12. Ferenci P. Treatment of hepatitis C in difficult-totreat patients.Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284-92.

13. Feld J.J., Moreno C., Trinh R., Tam E., Bourgeois S., Horsmans Y., Elkhashab M., Bernstein D.E., Younes Z., Reindollar R.W., Larsen L., Fu B., Howieson K., Polepally A.R., Pangerl A., Shulman N.S., Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016 Feb;64(2):3017. doi: 10.1016/j.jhep.2015.10.005. Epub 2015 Oct 22.

14. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C. et al. PEARL-III Study; PEARLIV Study.ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983-92.

15. Zeuzem S., Jacobson I.M., Baykal T., Marinho R.T., Poordad F., Bourlière M., Sulkowski M.S., Wedemeyer H., Tam E., Desmond P., Jensen D.M., Di Bisceglie A.M., Varunok P., Hassanein T., Xiong J., Pilot-Matias T., DaSilva-Tillmann B., Larsen L., Podsadecki T., Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/ NEJMoa1401561. Epub 2014 Apr 10.

16. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K., Shiffman M.L., Wedemeyer H., Berg T., Yoshida E.M., Forns X., Lovell S.S., Da Silva-Tillmann B., Collins C.A., Campbell A.L., Podsadecki T., Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/ NEJMoa1402869. Epub 2014 Apr 11.

17. US Food and Drug Administration Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634. htm (accessed 17 April 2016). European Medicines Agency (EMA) Committee for medicinal products for human use (CHMP) assessment report. Viekirax. International non-proprietary name: ombitasvir/paritaprevir/ritonavir. Procedure No. EMEA/H/C/003839/0000. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-Public_assessment_report/human /003839/WC500183999.pdf (accessed 17 April 2016). European Medicines Agency (EMA) Committee for medicinal products for human use (CHMP) assessment report. Exviera. International non-proprietary name: dasabuvir. Procedure No. EMEA/H/C/003837/0000. Available at: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Public_assessment_report/ human/003837/WC500182235.pdf (accessed 17 April 2016).